We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Promis Neurosciences Inc (PMN) NPV

Sell:0.19 CAD Buy:0.19 CAD Change: 0.01 CAD (5.26%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Sell:0.19 CAD
Buy:0.19 CAD
Change: 0.01 CAD (5.26%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Sell:0.19 CAD
Buy:0.19 CAD
Change: 0.01 CAD (5.26%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.

Contact details

M4S 3E2
+1 (416) 8476898

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
79.87 million CAD
Shares in issue:
431.73 million
Toronto Stock Exchange
Canadian dollars

Key personnel

  • Eugene Williams
    Executive Chairman of the Board
  • Elliot Goldstein
    President, Chief Executive Officer, Director
  • Neil Cashman
    Co-Founder, Chief Scientific Officer, Director
  • Daniel Geffken
    Chief Financial Officer
  • Johanne Kaplan
    Chief Development Officer
  • James Kupiec
    Chief Medical Officer
  • David Wishart
    Chief Physics Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.